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Isoform-selective inhibitors of NOS enzymes are desirable as research tools and for potential therapeutic purposes.
Vinyl-l-N-5-(1-imino-3-butenyl)-l-ornithine (L-VNIO) and Nw-propyl-L-arginine (NPA) purportedly have good selectivity for
neuronal over endothelial NOS under cell-free conditions, as does N-[(3-aminomethyl)benzyl]acetamidine (1400W), which is
primarily an inducible NOS inhibitor. Although used in numerous investigations in vitro and in vivo, there have been
surprisingly few tests of the potency and selectivity of these compounds in cells. This study addresses this deficiency and
evaluates the activity of new and potentially better pyrrolidine-based compounds.
EXPERIMENTAL APPROACH
The inhibitors were evaluated by measuring their effect on NMDA-evoked cGMP accumulation in rodent hippocampal slices, a
response dependent on neuronal NOS, and ACh-evoked cGMP synthesis in aortic rings of the same animals, an endothelial
NOS-dependent phenomenon.
KEY RESULTS
L-VNIO, NPA and 1400W inhibited responses in both tissues but all showed less than fivefold higher potency in the
hippocampus than in the aorta, implying useless selectivity for neuronal over endothelial NOS at the tissue level. In addition,
the inhibitors had a 25-fold lower potency in the hippocampus than reported previously, the IC50 values being approximately
1 mM for L-VNIO and NPA, and 150 mM for 1400W. Pyrrolidine-based inhibitors were similarly weak and nonselective.
CONCLUSION AND IMPLICATIONS
The results suggest that L-VNIO, NPA and 1400W, as well as the newer pyrrolidine-type inhibitors, cannot be used as neuronal
NOS inhibitors in cells without stringent verification. The identification of inhibitors with useable selectivity in cells and tissues
remains an important goal.
Abbreviations
1400W, N-[(3-aminomethyl)benzyl]acetamidine; aCSF, artificial CSF; eNOS, endothelial NOS; eNOS-/-, endothelial NOS
knockout; FX-5043, 6-{[(3R,4R)-4-(2-{[2,2-difluoro-2-(3-fluorophenyl)ethyl]amino}ethoxy)pyrrolidin-3-yl]methyl}-4-
methylpyridin-2-amine; iNOS, inducible NOS; JK-5, 6-{[(3R,4R)-4-(2-{[2-(3-chloro-5-fluorophenyl)-2,2-difluoroethyl]
amino}ethoxy)pyrrolidin-3-yl]methyl}-4-methylpyridin-2-amine; L-VNIO, vinyl-l-N-5-(1-imino-3-butenyl)-l-ornithine;
nNOS, neuronal NOS; NPA, Nw-propyl-l-arginine
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Introduction
NO is an intercellular transmitter of widespread importance
to mammalian physiology. NO signals are predominantly
generated by NOS enzymes and are transduced by cGMP
following activation of NO-targeted guanylyl cyclase
(Garthwaite, 2008; Friebe and Koesling, 2009), also still
known by its homogenate-based name, soluble guanylyl
cyclase. Three isoforms of NOS have been identified, namely
the neuronal (nNOS), endothelial (eNOS) and inducible
(iNOS) subtypes. All three catalyse the mono-oxygenation of
L-arginine to NO and share a common general structure
(Alderton et al., 2001), although variations in their regulation
and cellular distribution are thought to yield a diversity of
NO signals with different, and sometimes opposing, physi-
ological and/or pathological consequences. In the brain, for
example, eNOS and nNOS may contribute to hippocampal
synaptic plasticity in a temporally distinct, but complemen-
tary, manner (Hopper and Garthwaite, 2006); whereas, under
ischaemic conditions, eNOS and nNOS appear to have oppos-
ing beneficial and detrimental effects respectively (Huang
et al., 1994; 1996). Accordingly, isoform-selective NOS inhibi-
tors are highly desirable, both as tools in NO research and for
the potential treatment of pathologies deemed to involve
increased NO concentrations (Hobbs et al., 1999; Vallance
and Leiper, 2002).
Under physiological conditions, and in the absence of
immune challenge, eNOS and nNOS predominate (MacMick-
ing et al., 1997). Selective inhibitors for eNOS have yet to be
found, although several apparently potent and selective
nNOS inhibitors have been identified using cell-free assays.
Amongst them, three commonly used compounds are vinyl-
l-N-5-(1-imino-3-butenyl)-l-ornithine (L-VNIO; KI for isolated
rat nNOS = 0.1 mM, bovine eNOS = 12 mM and mouse
iNOS = 60 mM; Babu and Griffith, 1998b), Nw-propyl-L-
arginine (NPA; KI for isolated bovine nNOS = 0.06 mM, bovine
eNOS = 8.5 mM and murine iNOS = 180 mM; Zhang et al.,
1997) and N-[(3-aminomethyl)benzyl]acetamidine (1400W),
which is primarily used as a iNOS inhibitor but which has
moderate selectivity for nNOS over eNOS (KI for human
nNOS = 2 mM and human eNOS = 50 mM; Garvey et al.,
1997). In tissues, nNOS-selective concentrations of L-VNIO
(0.1 mM), NPA (1 mM) and 1400W (1 mM) have been defined
by their ability to inhibit NMDA-induced cGMP accumula-
tion in rodent hippocampal slices, a presumed nNOS-
dependent response (Huang et al., 1993), but leave intact
ACh-evoked cGMP synthesis in aortic rings (Hopper and
Garthwaite, 2006), a response assumed to be eNOS-
dependent (Furchgott and Zawadzki, 1980; Huang et al.,
1995). The compounds have now been used to selectively
inhibit nNOS in over 40 studies in vitro and in vivo (see
Discussion for examples). There is, however, a surprising lack
of tests of the selectivity and potency of the compounds in
intact cells or tissues.
The present study was prompted by the observation
(Pigott, 2012) that a form of hippocampal synaptic plasticity
could be inhibited by a broad-spectrum NOS inhibitor but
was sustained in eNOS knockout mice and in the presence of
a concentration of L-VNIO (0.1 mM) previously found to
inhibit the NMDA-evoked cGMP response in hippocampal
slices (Hopper and Garthwaite, 2006). To provide a positive
control for the activity of L-VNIO, tests of its potency against
NMDA-stimulated cGMP accumulation in hippocampal slices
were repeated. In the light of the findings with this com-
pound, the potency and selectivity of NPA, 1400W and
potentially superior, pyrrolidine-based inhibitors (called here
FX-5043 and JK-5; Xue et al., 2010a) were also evaluated. In
disagreement with previous results (Hopper and Garthwaite,
2006), we found that L-VNIO, NPA and 1400W are inad-
equately (<5-fold) selective for nNOS over eNOS in intact
tissues to be of use diagnostically. FX-5043 and JK-5 were also
found to be unsuitable for use as nNOS inhibitors at the tissue
level.
Methods
The drug/molecular target nomenclature used in this manu-
script conforms to British Journal of Pharmacology’s Guide to
Receptors and Channels (Alexander et al., 2011).
Animals
All work was compliant with British Home Office regulations
on laboratory animal use and welfare, and every effort to
reduce the number of animals used was made. Methods and
results have been reported in accordance with ARRIVE guide-
lines (McGrath et al., 2010). Experiments were conducted
using a total of 18, 6- to 8-week-old, male C57Bl/6 mice and
28, 9- to 10-day-old, male Sprague–Dawley rats (both from
Charles River, Kent, UK). Six male, 6- to 14-week-old, mice
lacking functional eNOS (eNOS-/-) were kindly provided by
Dr Adrian Hobbs (University College London, London, UK;
see Huang et al., 1995) and Dr Michael Emerson (Imperial
College London, London, UK; strain 002684 from Jackson
Laboratory, ME, USA). Five age-, sex- and strain-matched
wild-type control mice were obtained from Harlan (Cam-
bridgeshire, UK) or Charles River. Genotyping was done using
the PCR and agarose gel electrophoresis. All animals were
housed in cages with soft bedding in a 12 h light/dark cycle
with food and water available ad libitum.
Chemicals
ACh chloride, L-arginine hydrochloride, erythro-9-(2-
hydroxy-3-nonyl)adenine hydrochloride (EHNA), IBMX and
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were
purchased from Sigma-Aldrich (Dorset, UK). NMDA and
L-nitroarginine (L-NNA) were obtained from Tocris Cookson
(Bristol, UK). N-[(3-Aminomethyl)benzyl]acetamidine dihy-
drochloride (1400W), 2-[(3,4-dimethoxyphenyl)methyl]-7-
[(1R)-1-hydroxyethyl]-4- phenylbutyl]-5-methyl-imidazo[5,
1-f][1,2,4]triazin-4(1H)-one (BAY 60-7550) and Nw-propyl-L-
arginine (NPA) were from Cayman Chemical (Ann Arbor, MI)
and 2-(N,N-diethylamino)-diazenolate-2-oxide diethylammo-
nium salt (DEA/NO) was from Enzo Life Sciences (Exeter,
UK). Vinyl-l-N-5-(1-imino-3-butenyl)-L-ornithine hydrochlo-
ride (L-VNIO) was purchased from Axxora or Cambridge
Bioscience (Cambridge, UK). 6-{[(3R,4R)-4-(2-{[2,2-Difluoro-2-
(3-fluorophenyl)ethyl]amino}ethoxy)pyrrolidin-3-yl]methyl}-
4-methylpyridin-2-amine trihydrochloride (FX-5043)
and 6-{ [ (3R,4R ) -4- (2- { [2- (3-chloro-5-fluorophenyl) -2,
2-difluoroethyl]amino}ethoxy)pyrrolidin-3-yl ]methyl } -4-
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methylpyridin-2-amine trihydrochloride (JK-5) were kind
gifts from Prof Richard Silverman (Northwestern University,
IL). Stock solutions were made in either dimethyl sulphoxide
(BAY 60–7550, FX-5043, IBMX, JK-5, L-VNIO, NPA, ODQ),
equimolar HCl (L-NNA), equimolar NaOH (NMDA), 10 mM
NaOH (DEA/NO) or H2O (ACh, L-arginine, EHNA, 1400W).
Except in experiments in which controls for the vehicle were
included; the concentrations of stock solutions were at least
100-fold higher than the final concentrations.
Tissue preparation
Animals were killed by cervical dislocation and decapitation.
For experiments using mouse hippocampal slices, the brains
were removed, and hippocampi were dissected out into ice-
cold artificial CSF (aCSF) containing (in mM) 120 NaCl, 2.5
KCl, 1.3 MgCl2, 1 NaH2PO4, 26 NaHCO3, 10 D-glucose and 2
CaCl2, equilibrated with 95% O2/5% CO2 to pH 7.4 (at 37°C).
Transverse slices (400 mm-thick) were cut from the middle of
the hippocampi using a vibratome (Series 100 Sectioning
System, Technical Products International, MO) and then
allowed to recover for 1–2 h at room temperature on a nylon
net submerged in aCSF, which was continuously bubbled
with 95% O2/5% CO2.
For all other experiments, the hippocampi, cerebellum or
aorta were dissected out into aCSF comprising (in mM) 120
NaCl, 2 KCl, 1.19 MgSO4, 26 NaHCO3, 1.18 KH2PO4, 11
D-glucose and 2 CaCl2 equilibrated with 95% O2/5% CO2 to
pH 7.4 (at 37°C). Transverse, hippocampal or sagittal, cerebel-
lar slices (both 400 mm thick) were cut with a tissue chopper
(McIlwain, Campden Instruments, Loughborough, UK) and
thoracic aortic rings (2–3 mm-thick; free from excess blood
and connective tissues) using a razor blade. Tissues were then
recovered for 1–2 h in flasks of aCSF held in a shaking water
bath (37°C) and continuously perfused with 95% O2/5% CO2.
cGMP measurement
Methods were adapted from Hopper and Garthwaite (2006).
Brain slices or aortic rings were randomly distributed to flasks
of oxygenated aCSF held in a shaking water bath. For mouse
hippocampal slices, the temperature was 30°C, set to match
the conditions used for electrophysiology and the experi-
ments of Hopper and Garthwaite, whereas 37°C was used for
all other tissues. nNOS-dependent cGMP production was
stimulated in brain slices by exposure to NMDA at a concen-
tration and for a duration (100 mM, 2 min) shown previously
to be maximal for the cGMP response in rat hippocampal
slices (Hopper and Garthwaite, 2006). For experiments with
aortic rings, ACh (10 mM, 1 min) was used to stimulate eNOS
and the NO donor, DEA/NO (100 mM, 5 min), to directly
activate the NO-targeted guanylyl cyclase. In order to
improve the cGMP signal-to-noise ratio, the rings were pre-
incubated with the non-selective phosphodiesterase inhibi-
tor, IBMX and hippocampal slices with one of two inhibitors
of PDE-2 (BAY 60–7550, or EHNA), the enzyme primarily
responsible for cGMP hydrolysis in the hippocampus (Van
Staveren et al., 2001; Van Staveren et al., 2003). PDE inhibi-
tion was not necessary to resolve the very large cGMP
response observed in cerebellar slices (Garthwaite and Balazs,
1978). Concentrations of all drugs are given in the figure
legends; unless otherwise stated, tissues were pre-incubated
with inhibitors for 15 min.
Within 30 s of the end of stimulation, tissues were indi-
vidually inactivated by submersion in 200 mL boiling buffer
containing 50 mM Tris–HCl and 4 mM EDTA (pH 7.4 at room
temperature). cGMP was measured by radioimmunoassay
and normalized to the total tissue protein measured using a
bicinchoninic acid protein assay kit (Perbio Science, North-
umberland, UK). Unstimulated cGMP levels and the effect
of the non-selective NOS inhibitor L-NNA (100 mM) on
the stimulated cGMP response were measured in every
experiment.
Chemical analysis of nNOS inhibitors
High-performance liquid chromatography-mass spectrom-
etry was performed by Dr Matthew Gooding (University
College London, London, UK) using a 6100 Series LC-Mass
Spectrometer and a C-18 column (Agilent Technologies,
Cheshire, UK). The mobile phase comprised a methanol to
water gradient and 0.1% formic acid (which protonated the
sample compounds).
Statistics
Data were obtained from tissues from at least three different
animals and are reported as mean values  SEM. Statistical
significance was assessed using analysis of variance (ANOVA)
with an appropriate post hoc test, or a two-tailed t-test. Sig-
nificance was concluded when P < 0.05. IC50 and Hill slope
values (SEM) were calculated from logistic fits. In some
instances, successful fitting required the Hill slope to be set
equal to 1 (see Table 1); adjusted R2 statistics of the fits were
0.880–0.995.
Results
L-VNIO, 1400W and NPA
In accordance with previous reports (East and Garthwaite,
1991; Hopper and Garthwaite, 2006), NMDA (100 mM)
evoked a significant accumulation of cGMP in adult mouse
hippocampal slices incubated with the PDE-2 inhibitor BAY
60–7550 (1 mM). The response was blocked by the non-
selective NOS inhibitor L-NNA (100 mM), or the inhibitor of
NO-targeted guanylyl cyclase ODQ (10 mM). The basal/
unstimulated and NMDA-evoked cGMP levels were not sig-
nificantly different between slices from eNOS-/- and matched
wild-type mice (Figure 1). Considering this result, together
with findings that hippocampal slices prepared from healthy
animals lack iNOS (Hopper and Garthwaite, 2006), and that
>90% of hippocampal, Ca2+-induced NOS activity is abolished
in mice lacking the major nNOS splice variant (Huang et al.,
1993), it was concluded that the NMDA-evoked cGMP
response was nNOS-dependent. Unexpectedly, pretreatment
of slices with L-VNIO (0.1 mM) or a second NOS inhibitor,
1400W (1 mM), each at a concentration shown previously to
inhibit NMDA-evoked cGMP accumulation in adult rat hip-
pocampal slices by 80–90% (Hopper and Garthwaite, 2006),
had no effect on the magnitude of the NMDA-evoked cGMP
response (Figure 2A).
The only obvious methodological difference between the
present study and that of Hopper and Garthwaite (2006) was
the PDE-2 inhibitor used to resolve the cGMP signal. To test
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whether this difference could account for the variation in
L-VNIO potency, we substituted BAY 60–7550 in our experi-
ments with the inhibitor used by Hopper and Garthwaite
(EHNA at 300 mM). The NMDA-evoked and basal cGMP levels
in the EHNA-pretreated slices were around half those
observed in the BAY 60–7550-treated slices, presumably
reflecting the superior potency of the latter inhibitor (Boess
et al., 2004), but were in good agreement with those reported
by Hopper and Garthwaite (2006). In contrast with the results
of Hopper and Garthwaite (2006), neither L-VNIO nor 1400W
had any significant effect on the cGMP response in the
EHNA-pretreated slices (Figure 2B).
The difference between the results in the two studies
might also have been explained were the compounds used in
either study inauthentic. We obtained identical results,
however, using two different batches of L-VNIO and 1400W
(see Figure 2 legend). Furthermore, the molecular mass, integ-
rity and purity of one batch of each compound were substan-
tiated using high-performance liquid chromatography and
mass spectrophotometry (Figure 3).
To determine whether a higher concentration of L-VNIO
could effect selective nNOS inhibition, we required a cell-
based measure of the action of the compound on eNOS.
Previously, the cGMP response to ACh in aortic rings has
been used (Hopper and Garthwaite, 2006). ACh is a standard
means of activating eNOS in endothelial cells (Furchgott and
Zawadzki, 1980; Huang et al., 1995); but, curiously, informa-
tion on the NOS isoforms involved in the cGMP response to
ACh in aorta (or any other blood vessel) seems to be absent
from the literature. To address this omission, we used eNOS-/-
mice. In aortic rings prepared from wild-type mice and pre-
incubated with the general PDE inhibitor IBMX (1 mM), ACh
(10 mM) generated a significant rise in cGMP that was abol-
ished by L-NNA (100 mM); this response was absent from
aortic rings prepared from eNOS-/- mice (Figure 4). Direct
stimulation of NO-targeted guanylyl cyclase using an NO
donor, DEA/NO (100 mM), yielded large increases in cGMP
that did not differ significantly in rings from wild-type and
eNOS-/- mice, showing that the capacity of the two tissues to
generate cGMP in response to NO was similar. The ACh-
induced response in wild-type aortic rings was about seven-
fold smaller than achievable with the NO donor, consistent
with endogenous NO operating in the very low part of its
concentration-response curve, probably in the picomolar
range (Wood et al., 2011).
Having verified that the NMDA-evoked cGMP response in
mouse hippocampal slices was nNOS-dependent (Figure 1),
and the ACh-evoked cGMP accumulation in mouse
aortic rings was eNOS-dependent (Figure 4), concentration–
Table 1
Potency and selectivity of alleged nNOS inhibitors
Inhibitor Species




(e/nNOS)aIC50 (mM) Hill slope IC50 (mM) Hill slope
L-VNIO Mouse 1.2  0.6 1b 1.9  0.4d 1b 1.6 120
L-VNIO Rat 0.27  0.04 1.1  0.1 0.9  0.1c 1.0  0.2 3.3
1400W Rat 154  78 0.7  0.4 744  52c 0.8  0.1 4.8 25
NPA Rat 1.3  0.5 0.9  0.2 4.3  2.2 1b 3.3 149
aData taken from the original description of each compound (Garvey et al., 1997; Zhang et al., 1997; Babu and Griffith, 1998b) using cell-free
assays.
bValue fixed to enable fitting.
cUnpaired t-test, P < 0.001 compared to the IC50 measured using the same compound in rat hippocampus.
dUnpaired t-test, P < 0.05 (P = 0.04) compared to the IC50 for L-VNIO in rat aorta.
ehipp = hippocampus.
Figure 1
nNOS-dependent, NMDA-induced cGMP accumulation in adult
mouse hippocampal slices. Slices were pre-incubated with the PDE-2
inhibitor BAY 60–7550 (1 mM) for 10 min. NMDA (100 mM, 2 min)
induced a significant increase in cGMP from basal/unstimulated
levels (ANOVA with Tukey–Kramer test, P < 0.001). This increase was
prevented by the non-selective NOS antagonist, L-NNA (100 mM), or
the NO-targeted guanylyl cyclase inhibitor, ODQ (10 mM; ANOVA with
Tukey–Kramer test, P > 0.05 compared with basal). Basal and
NMDA-induced cGMP levels did not differ significantly between
slices from eNOS-deficient (eNOS-/-) and matched wild-type
(eNOS+/+) mice (unpaired t-tests, eNOS-/- vs. eNOS+/+, P > 0.05).
Numbers above error bars are n-values.
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response curves for L-VNIO in both preparations were com-
piled. Using tissues from the same adult mice, it was found
that the cGMP responses to NMDA in hippocampal slices and
to ACh in aortic rings were inhibited by L-VNIO with very
similar potencies, the IC50 values being 1–2 mM (Figure 5A
and Table 1).
In view of these results, tests of two other inhibitors,
1400W and NPA, that are reportedly selective for the cGMP
response to NMDA in hippocampus over the response to ACh
in aorta (Hopper and Garthwaite, 2006), were made. These
experiments used immature rats, which provided more hip-
pocampal slices and aortic rings than did adult mice. As in
adult mice, L-VNIO was effectively non-selective in the rat
tissues (Figure 5B, Table 1). Comparable non-selectivity was
apparent with 1400W and NPA (Figure 5C and D, Table 1).
The results in hippocampal slices could be generalised to
other nNOS-mediated responses based on testing the effect of
L-VNIO on NMDA-evoked, nNOS-dependent (Morton and
Bredt, 1998) cGMP accumulation in immature rat cerebellar
slices. The IC50 in cerebellum was 1.3 mM (Figure 6A legend),
a value fivefold higher than in hippocampus and similar to
that found in aorta (0.9 mM).
One factor that could account for the differing potencies,
and therefore selectivities, of all three compounds between
the present study and that of Hopper and Garthwaite (2006)
is variation in the intracellular L-arginine concentration in
the brain slice preparations (the aortic data being compat-
ible), because all three inhibitors compete with the substrate
Figure 2
Effect of 0.1 mM L-VNIO and 1 mM 1400W on NMDA-evoked cGMP
accumulation in adult mouse hippocampus. (A) Hippocampal slices
were pretreated with BAY 60–7550 (1 mM) for 10 min. NMDA
(100 mM, 2 min) induced a significant increase in cGMP from basal
levels (P < 0.001). Concentrations of L-VNIO (0.1 mM) or 1400W
(1 mM) that have been previously reported to reduce the NMDA-
evoked response in hippocampal slices by 80–90% had no significant
effect (P > 0.05 compared with control), although the response was
abolished by L-NNA (100 mM; P > 0.05 compared with basal). The
data have been compiled from two separate experiments, each using
different batches of L-VNIO and 1400W. Analysed separately, neither
batch of L-VNIO or 1400W had any significant effect on the NMDA-
evoked cGMP response (P > 0.05 compared with control). (B) L-VNIO
(0.1 mM) and 1400W (1 mM) were also without effect on the NMDA-
evoked cGMP response when EHNA (300 mM, 10 min) was used in
place of BAY 60–7550 (P > 0.05 compared with control). As in panel
A, NMDA generated a significant accumulation of cGMP compared
with basal (P < 0.001) that was blocked by L-NNA (P > 0.05 com-
pared with basal). Statistics are ANOVA with Tukey–Kramer test.
Numbers above error bars are n-values.
Figure 3
Chemical analysis of L-VNIO and 1400W. High-performance liquid
chromatography of one batch of the L-VNIO (A) or 1400W (B) used
in Figure 2 yielded a single major peak in each chromatogram (upper
panels). Analysis of these peaks by mass spectrometry revealed that
they comprised a molecular ion with a mass–charge ratio equivalent
to the predicted molecular mass of the relevant compound (note
that the molecular ions were protonated by formic acid in the
running buffer). See insets for the chemical structures and predicted
molecular mass (MM) of each compound. Relative abundance has
been normalised to the maximum value recorded (100%).
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amino acid for binding to nNOS (Garvey et al., 1997; Zhang
et al., 1997; Babu and Griffith, 1998b). Unfortunately, there
are currently no reliable means to deplete intracellular
L-arginine so the experiments examined the effect of increas-
ing the availability of L-arginine in hippocampal slices by
adding it to the incubation medium. At a concentration
shown previously to be maximal for nNOS-dependent cGMP
accumulation in rat cerebellar slices (100 mM; Garthwaite
et al., 1989), L-arginine caused a twofold increase in the
amplitude of the cGMP response to NMDA and around a
60-fold decrease in the inhibitory potency of L-VNIO
(Figure 6B). These effects of L-arginine are in excellent agree-
ment with previous studies using other NOS inhibitors
(L-NNA and L-methylarginine) in immature rat cerebellar
and hippocampal slices (Garthwaite et al., 1989; East and
Garthwaite, 1990; East and Garthwaite, 1991).
Gem-difluorinated, pyrrolidine-based
compounds
A series of pyrrolidine-based NOS inhibitors have recently
been reported to have good selectivity for nNOS over eNOS in
cell-free assays and improved cell permeability relative to
previous compounds of this chemical class (Ji et al., 2009;
Lawton et al., 2009; Xue et al., 2010a,b). Considering the
above negative results with L-VNIO, NPA and 1400W,
we tested the potency and selectivity of the best of these
new compounds, FX-5043 (Figure 7C), which has a reported
780-fold selectivity for isolated nNOS over eNOS (KI for
rat nNOS = 0.08 mM under cell-free conditions; Xue et al.,
2010a), and a structurally related substance, JK-5. To circum-
vent the requirement for a PDE inhibitor to resolve the cGMP
response, slices of immature rat cerebellum, which produces
exceptionally high amplitude (Garthwaite, 1982), nNOS-
dependent (Morton and Bredt, 1998), NMDA-evoked cGMP
signals, were used.
As expected, the NMDA-induced rise in cerebellar cGMP
was blocked by L-NNA (100 mM) and inhibited by FX-5043,
and JK-5 (with 20 min pre-incubation) in a concentration-
dependent manner (IC50 approximately 30 mM; Figure 7A).
Inhibition by FX-5043 (30 mM) increased exponentially with
Figure 4
eNOS-dependent, ACh-induced cGMP accumulation in adult mouse
aortic rings. Rings were pre-incubated with the non-selective PDE
inhibitor IBMX (1 mM) for 20 min. In slices from wild-type (eNOS+/+)
mice, ACh (10 mM, 1 min) generated a significant increase in cGMP
from basal (ANOVA with Tukey–Kramer test, P < 0.001) that was abol-
ished by the non-selective NOS inhibitor, L-NNA (100 mM, 30 min
pretreatment; P > 0.05 compared with basal). The response to ACh
was absent in slices from eNOS-/- mice (ANOVA with Tukey–Kramer
test, ACh vs. basal or L-NNA: P > 0.05). The response of eNOS+/+ and
eNOS-/- slices to the NO donor, DEA/NO (100 mM, 5 min), did not
differ significantly (unpaired t-test, P > 0.05). Numbers above bars
are n-values; note the break in the y-axis.
Figure 5
Selectivity of L-VNIO, 1400W and NPA for nNOS over eNOS. Hip-
pocampal slices were pre-incubated with the PDE-2 inhibitor, BAY
60–7550 (1 mM for adult mouse; 10 nM for immature rat) and
stimulated with NMDA (100 mM, 2 min). Aortic rings were pre-
treated with the non-selective phosphodiesterase inhibitor, IBMX
(1 mM), and stimulated with ACh (10 mM, 1 min). L-VNIO (A–B),
1400W (C) and NPA (D; all pre-incubated for 25 min) inhibited the
cGMP response to NMDA in hippocampus and to ACh in aorta in a
concentration-dependent manner with similar potency (see Table 1
for IC50 and Hill slope values). In all experiments, L-NNA (100 mM;
25 min) reduced the cGMP response to NMDA or ACh by >90%
(control vs. L-NNA, P < 0.001). Asterisks indicate the lowest concen-
tration of each compound at which cGMP was not significantly
different from the mean value in L-NNA-treated slices (P > 0.05).
Obelisks (†) signify the lowest concentration at which L-VNIO or NPA
caused a significant reduction in ACh-evoked cGMP accumulation in
aortic rings (P < 0.05–0.001). Statistics are ANOVA with Tukey–Kramer
test. Within each panel, hippocampal slices and aortic rings were
prepared from the same animals. Y-axes are colour-coded according
to the tissue (see key in panel A).
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pre-incubation time up to 100 min (Figure 7B), consistent
with a slow diffusion into the cells and implying that stand-
ard pre-incubation times were insufficient for complete pen-
etration. With a 90 min pre-incubation, the NMDA-induced
cGMP response in cerebellar slices was abolished by 100 mM
FX-5043 or JK-5 (Figure 8A). The same concentrations also
eliminated the cGMP response to ACh in aortic rings
(Figure 8B), implying non-selectivity in intact tissues.
Discussion
The major finding of this study is that the purported nNOS
inhibitors, 1400W, NPA and L-VNIO are inadequately (<5-
fold) selective for nNOS over eNOS in intact tissues to be of
use diagnostically (Figure 5 and Table 1). The results chal-
lenge the marketing of the compounds as ‘potent, selective
inhibitor[s] of nNOS’ (e.g. by Cayman Chemical Company),
and the widespread presumption that they selectively attenu-
ate nNOS activity in vitro and in vivo, for example in brain
(e.g. Steinert et al., 2008; Chiang et al., 2009; Le Roux et al.,
2009; Romberg et al., 2009; Taqatqeh et al., 2009; Cheng
et al., 2011; Neitz et al., 2011), the peripheral nociceptive
pathway (e.g. Lima et al., 2010; Romero et al., 2011), heart
(e.g. Herring et al., 2000; Choate et al., 2001; Danson and
Paterson, 2003; Lu et al., 2009), kidney (e.g. Kakoki et al.,
2001; Shi et al., 2006; Foster et al., 2009; Wang and Cupples,
2009; Dautzenberg et al., 2011; Yamaleyeva et al., 2012) and
gut (Mathison et al., 2004; Hatanaka et al., 2006; Fornai et al.,
2007; Kato et al., 2009).
The lack of selectivity that we observed is discordant with
the original characterization of all three compounds using
cell-free assays (Garvey et al., 1997; Zhang et al., 1997; Babu
and Griffith, 1998b: see reported selectivities in Table 1).
However, other biochemical studies using isolated NOS
enzymes are consistent with our findings. Notably, Boer et al.
(2000) estimate the selectivity of L-VNIO, NPA and 1400W for
isolated human nNOS over eNOS to be 3, 4 and 10, respec-
tively, values that are in good agreement with our own
(Table 1). Additionally, Kotthaus et al. (2008) have observed
that an L-VNIO concentration sufficient to reduce recom-
binant rat nNOS activity by 94% (100 mM) also inhibited
Figure 6
Potency of L-VNIO in cerebellum versus hippocampus and the effect
of L-arginine. (A) Rat cerebellar slices were pre-incubated with L-VNIO
for 25 min and stimulated with NMDA (100 mM, 2 min). As in rat
hippocampal slices (data from Figure 5B re-plotted here for ease of
comparison), L-VNIO inhibited the cGMP response to NMDA in the
cerebellum concentration-dependently. The IC50 was 1.3  0.14 mM
(P < 0.001 compared with the fivefold lower value in rat hippocam-
pal slices by unpaired t-test) and the Hill slope, 1.7  0.15. (B) Rat
hippocampal slices were pretreated with L-arginine (100 mM,
25 min), L-VNIO (20 min) and BAY 60–7550 (15 min). L-arginine
caused an approximate 60-fold decrease in the potency of L-VNIO
(IC50 value = 16  6 mM; P < 0.05 compared with the IC50 in control
hippocampal slices by unpaired t-test). The Hill slope was set to 1 to
enable accurate fitting. The control data shown in black are from
Figures 5B and 6A. In panels A and B, L-NNA (100 mM; 20–25 min)
reduced the cGMP response to NMDA by >90% (control vs. L-NNA,
P < 0.001). Y-axes are colour-coded according to the experimental
conditions.
Figure 7
Potency of pyrrolidine-based nNOS inhibitors in intact tissues. (A) In
rat cerebellar slices, the cGMP response to NMDA (100 mM, 2 min)
was inhibited by FX-5043 and JK-5 (20 min pre-incubation) in a
concentration-dependent manner (IC50 values both approximately
30 mM). (B) Inhibition of cGMP accumulation by 30 mM FX-5043
increased exponentially with pre-incubation time (note logarithmic
x-axis). (C) Chemical structures of FX-5043 and JK-5. Numbers above
error bars indicate n-values.
BJPNon-selectivity of neuronal NO synthase inhibitors
British Journal of Pharmacology (2013) 168 1255–1265 1261
bovine eNOS by 45%. In contrast with the original reports
(Zhang et al., 1997; Babu and Griffith, 1998b), Babu et al.
(1999) have found that NPA is only around 9-fold selective
for isolated nNOS over eNOS and Brzozowski et al. (2011)
that L-VNIO is only 25-fold more potent for human nNOS in
cell lysates than for purified eNOS. Conversely, Brzozowski
et al. (2011) also report that 1400W is substantially more
selective for nNOS over eNOS (332-fold) than was originally
observed by Garvey et al. (1997).
It is unclear why the selectivity of the compounds varies
so greatly between different cell-free assays. A comparison of
the assay conditions used by Boer et al. (2000) and in the
original characterisation of the inhibitors (Garvey et al., 1997;
Zhang et al., 1997; Babu and Griffith, 1998b) reveals numer-
ous methodological differences in, for example, the NOS
preparation (i.e. crude lysate vs. purified protein) and species
of origin, the duration of pre-incubation with the inhibitors
(potentially important with time-dependent inhibitors such
as L-VNIO) and the concentrations of L-arginine and cofac-
tors, such as calmodulin.
With respect to cell-based analyses, our estimates of the
selectivity (and potency) of all three compounds conflict
most obviously with Hopper and Garthwaite (2006), who
found that 0.1 mM L-VNIO, 1 mM 1400W and 1 mM NPA (sub-
IC50 concentrations in our experiments; Figures 2 and 5;
Table 1) reduced nNOS-dependent, NMDA-evoked cGMP
accumulation in hippocampal slices by 80–90% but left intact
the cGMP response to ACh in aortic rings, which we now
confirm to be eNOS-dependent (Figure 4). It is unlikely that
our results suffer from experimenter error because the results
reported here using L-VNIO in rat hippocampus and aorta
were obtained independently by two operators (BP and KB),
several months apart. The possibility that our results were
confounded by inauthentic or impure compounds is also
excluded (see Results). Furthermore, our data are consistent
with the results of some other cell-based studies. In particular,
Overend and Martin (2007) have found a NPA IC50 of close to
10 mM both for nitrergic, endothelium-independent (pre-
sumed nNOS-dependent) and for bradykinin-induced (pre-
sumed eNOS-dependent) dilation of bovine ciliary artery (cf.
1 and 4 mM in our experiments). Also in line with our results
(Figure 5C), Fang and Silverman (2009) have found that 5 mM
1400W is insufficient to attenuate the activity of recom-
binant nNOS in a cell-based assay.
It is likewise difficult to dismiss the results of Hopper and
Garthwaite (2006) because the concentrations found to be
active in their experiments are consistent with substantial
functional data. For instance, Hopper and Garthwaite (2006)
found that 0.1 mM L-VNIO and 1 mM 1400W significantly
reduced long-term potentiation in hippocampal slices.
According with the compound affecting NOS, the reduction
in LTP caused by 1400W could be prevented by co-
application of an NO donor. Other groups using different in
vitro preparations have also reported a functionally inhibitory
effect of 0.1 mM L-VNIO (e.g. Le Roux et al., 2009; Taqatqeh
et al., 2009). The effects observed in these studies are coherent
with NOS inhibition, since the phenomena involved were
blocked by non-selective NOS inhibitors. Additionally, other
concentrations of L-VNIO (0.2 and 1 mM) that were insuffi-
cient to attenuate nNOS activity under our conditions
(Figure 5) have been found to inhibit NOS-dependent phe-
nomena in vitro (e.g. Foster et al., 2009; Romberg et al., 2009).
Rather, all these functional and biochemical data point to
an inherent variability in susceptibility to the nNOS inhibi-
tors between tissues, or between studies using the same tissue.
Our comparison of the potency of L-VNIO in hippocampus
and cerebellum (Figure 6A) shows further variation, in this
case between different brain regions. One plausible explana-
tion lies in the intracellular L-arginine concentration. The
amino acid is typically omitted from extracellular solutions
used to incubate tissues and intracellular variation could
result from differences in L-arginine export/loss (e.g. during
tissue preparation), uptake or metabolism. The high sensitiv-
ity of the IC50 for L-VNIO in hippocampus to addition of
Figure 8
Potent concentrations of FX-5043 and JK-5 are non-selective for
nNOS in intact tissues. (A) FX-5043 (abbreviated FX) or JK-5
(100 mM; 90 min pre-incubation) abolished the NMDA-evoked
cGMP response (P > 0.05 compared with basal). The vehicle (dime-
thyl sulphoxide, DMSO) had no effect (P > 0.05 compared with
control). (B) In aortic rings prepared from the same animals as used
in panel A and pretreated with IBMX (1 mM, 20 min), ACh (10 mM,
1 min) initiated a significant increase in cGMP (P < 0.001). At the
same concentrations as used in panel A (100 mM, 90 min), FX-5043
and JK-5 blocked the cGMP response to ACh (P > 0.05 compared
with basal levels). DMSO alone had no effect (P > 0.05 compared to
control). Statistics are ANOVA with Tukey–Kramer test. Numbers above
error bars indicate n-values.
BJP B Pigott et al.
1262 British Journal of Pharmacology (2013) 168 1255–1265
L-arginine (Figure 6B) is consistent with this explanation.
Hence, a lower intracellular L-arginine concentration in hip-
pocampal neurones, but not in aortic endothelial cells, in the
study of Hopper and Garthwaite (2006) compared with the
present one could explain the discrepancies in the potency
(and therefore selectivity) of the inhibitors.
Regardless of the precise explanation, our results clearly
compromise the use of these compounds as selective nNOS
inhibitors without rigorous controls for their activity and
selectivity. Furthermore, our results complicate the interpre-
tation of studies that have argued against (or ruled out) the
involvement of nNOS in phenomena on the basis of a lack of
effect of the inhibitors (e.g. Mathison et al., 2004; Fornai
et al., 2007; Kato et al., 2009; Cheng et al., 2011; Neitz et al.,
2011).
Unfortunately, there appear to be few, if any, alternative
nNOS inhibitors available. 7-Nitroindazole is widely used as a
nNOS inhibitor in vitro and in vivo (e.g. Doyle et al., 1996;
Steinert et al., 2008). Nevertheless, the compound is report-
edly non-selective (<5-fold) for isolated nNOS (see Alderton
et al., 2001; Brzozowski et al., 2011) and has off-target effects,
notably as a monoamine oxidase-B inhibitor (Castagnoli
et al., 1997). S-Methyl-L-thiocitrulline (Furfine et al., 1994) is
also used, albeit less frequently, to selectively inhibit nNOS in
vitro and in vivo, yet studies show that the compound is
<10-fold selective for isolated nNOS over eNOS (Furfine et al.,
1994; Boer et al., 2000; both using human NOS isozymes).
The use of other compounds with moderate or good selectiv-
ity for isolated nNOS, such as S,S′-1,4-phenylene-bis(1,2-
ethanediyl)bis-isothiourea (100-fold selectivity over eNOS;
tested using isolated human NOS by Boer et al., 2000),
1[2-(trifluoromethyl)phenyl]-1H-imidazole (TRIM; 38-fold
selectivity over eNOS determined with homogenates of
mouse cerebellum and bovine aortic endothelial cells; Handy
et al., 1995) and AR-R17477 (28-fold over eNOS using human
isozymes, Brzozowski et al., 2011; 100-fold for rat nNOS over
human eNOS in partially purified preparations, Reif et al.,
2000), is also hampered by problems such as a lack of specifi-
city (isothioureas, see Babu and Griffith, 1998a; TRIM, Mat-
sumura et al., 2008) and/or a lack of availability (AR-R17477).
Recently, a series of pyrrolidine-based compounds with
good selectivity for nNOS in cell-free assays and moderate cell
permeability have been reported (Xue et al., 2010a,b). Unfor-
tunately, tests with two of these inhibitors indicated non-
selectivity in intact tissues (Figures 7 and 8). Nonetheless, the
development of nNOS inhibitors is ongoing (Xue et al., 2011;
Annedi et al., 2012; Labby et al., 2012), and future tests of the
selectivity of these compounds in intact tissues may reveal
superior alternatives to the compounds currently available.
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